Middle East News Dispatch
SEE OTHER BRANDS

The most trusted news from the Middle East

Middle East News Dispatch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Dispatch.

Press releases published on April 27, 2025

Perseus Mining Proceeds with Development of Nyanzaga Gold Project

Perseus Mining Proceeds with Development of Nyanzaga Gold Project

Perth, April 28, 2025 (GLOBE NEWSWIRE) -- PERSEUS MINING PROCEEDS WITH DEVELOPMENT OF THE NYANZAGA GOLD PROJECT overview Perth, Western Australia/ April 28, 2025/ Perseus Mining Limited (ASX/TSX: PRU) is pleased to announce that a Final Investment Decision …

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based …

Israeli startups to compete for $1M prize from Startup World Cup

Israeli startups to compete for $1M prize from Startup World Cup

Leading VCs and Global Corporations to gather at Axis Tel Aviv for the annual startup investment conference to prove resilience of Israeli venture ecosystem TEL AVIV, ISRAEL, April 27, 2025 /⁨EINPresswire.com⁩/ -- One promising Israeli startup will have …

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

REDWOOD CITY, Calif., April 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced new clinical data for …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service